MNOV
MediciNova Inc.
NasdaqGM
People also watch:OPXACYTKTTHITRGTIDRA
6.09-0.16 (-2.56%)

After hours: 6.090.00 (0.00%) as of 4:42 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close6.25
Open6.16
Bid5.19 x 100
Ask306.00 x 2500
52wk Range2.62 - 10.16
Day's Range6.01 - 6.16
Volume87,526
Avg Vol (3m)170,931
As of 4:00 PM EDT. Market closed.
  • MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
    Capital Cube2 months ago

    MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016

    Click here to see latest analysisMediciNova, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -3.38 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.MNOV-US‘s earnings and EBITDA are both […] (Read more...) The post MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.

  • Zacks Small Cap Research3 months ago

    MNOV: Positive Trends Seen in Preliminary Data Presented on MN-166 in ALS

    On April 20, 2016, Dr. Benjamin Brooks presented interim data from the Phase 2 clinical trial of MN-166 in patients with amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 2016 Annual Meeting. The preliminary data analysis was conducted on 25 patients (20 on MN-166 + riluzole, 5 on placebo + riluzole) that had completed the six-month double blind portion of the study. MN-166 is an anti-inflammatory drug that has been used for more than 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.